Edgewise Therapeutics
About:
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Website: https://www.edgewisetx.com
Top Investors: Wellington Management, Deerfield, RA Capital Management, OrbiMed, Cormorant Asset Management
Description:
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Guided by its holistic drug discovery approach to targeting the muscle as an organ, Edgewise has combined its foundational expertise in muscle biology and small molecule engineering to build its proprietary, muscle focused drug discovery platform. Edgewise’s platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases.
$539M
$50M to $100M
Boulder, Colorado, United States
2017-01-01
info(AT)edgewisetx.com
Alan Russell, Badreddin Edris, Peter Thompson
51-100
2024-01-19
Public
© 2025 bioDAO.ai